The development of China's API industry has entered the 3.0 era.
The 1.0 era was dominated by the export of bulk basic APIs represented by antibiotics and vitamins.The 2.0 era featured the industrial chain depth improvement driven by the integration of API + Finished Dosage Form + CDMO.The 3.0 era sees Chinese API enterprises reconstructing the ecological development system of the global pharmaceutical industrial chain, evolving into leaders and pioneers of the pharmaceutical value chain.
Chinese API companies now provide custom APIs for global pharmaceutical firms in early-stage R&D; export advanced production technologies via technology licensing; independently complete high-barrier regulatory registrations in major markets such as Europe and the United States; and set up overseas R&D centers and production bases to achieve genuine localised operations.
This marks a profound transformation of China's API industry: from integrating into the global industrial chain to undertaking innovative and pivotal roles within it.
For China's API industry, transformation has arrived, and the sector is fully poised for new growth.
